ACET Adicet Bio, Inc.

NASDAQ
$2.50

Adicet Bio, Inc. (ACET) is expected to report earnings on February 4, 2027, after the market close. The consensus earnings estimate is a loss of $1.91 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -13.5% since its last earnings release on November 5, 2026.

Adicet Bio Missed Consensus Estimates
Thursday, November 5, 2026 · 4:10 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 4
Thursday · 4:10 PM ET
Earnings Whisper
-
vs ($1.91)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.80

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Adicet Bio, Inc.

Adicet Bio Inc. is a biotechnology company. It engages in discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet Bio Inc., formerly known as RESTORBIO INC, is based in Calif.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.